UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Bionomics Limited

(Name of Issuer)

Ordinary Shares**

(Title of Class of Securities)

09063M205**

(CUSIP Number)

Julien Höfer

Apeiron Investment Group Ltd.

Beatrice, at 66 & 67 Amery Street,

SLM1707, Sliema, Malta

+356 9960 9158

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 3, 2024

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

**

This CUSIP number has been assigned to the American depositary shares (“ADSs”) of the Issuer. Each ADS represents 180 Ordinary Share of the Issuer. No CUSIP number has been assigned to the Ordinary Shares of the Issuer.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes

 

 

 


CUSIP No. 09063M205    13D    Page 1 of 8 pages

 

 1    

 Names of Reporting Persons

 

 Apeiron Investment Group Ltd.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Malta

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7     

 Sole Voting Power

 

 0

    8   

 Shared Voting Power

 

 276,490,501

    9   

 Sole Dispositive Power

 

 0

   10   

 Shared Dispositive Power

 

 276,490,501

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 276,490,501

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 8.9%

14  

 Type of Reporting Person

 

 CO


CUSIP No. 09063M205    13D    Page 2 of 8 pages

 

 1    

 Names of Reporting Persons

 

 Apeiron Presight Capital Fund II, L.P.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7     

 Sole Voting Power

 

 0

    8   

 Shared Voting Power

 

 93,369,060

    9   

 Sole Dispositive Power

 

 0

   10   

 Shared Dispositive Power

 

 93,369,060

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 93,369,060

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 3.0%

14  

 Type of Reporting Person

 

 PN


CUSIP No. 09063M205    13D    Page 3 of 8 pages

 

 1    

 Names of Reporting Persons

 

 Presight Capital Management I, L.L.C.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7     

 Sole Voting Power

 

 0

    8   

 Shared Voting Power

 

 93,369,060

    9   

 Sole Dispositive Power

 

 0

   10   

 Shared Dispositive Power

 

 93,369,060

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 93,369,060

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 3.0%

14  

 Type of Reporting Person

 

 OO


CUSIP No. 09063M205    13D    Page 4 of 8 pages

 

 1    

 Names of Reporting Persons

 

 Fabian Hansen

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Germany

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7     

 Sole Voting Power

 

 0

    8   

 Shared Voting Power

 

 93,369,060

    9   

 Sole Dispositive Power

 

 0

   10   

 Shared Dispositive Power

 

 93,369,060

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 93,369,060

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 3.0%

14  

 Type of Reporting Person

 

 IN


CUSIP No. 09063M205    13D    Page 5 of 8 pages

 

 1    

 Names of Reporting Persons

 

 Christian Angermayer

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Federal Republic of Germany

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7     

 Sole Voting Power

 

 0

    8   

 Shared Voting Power

 

 276,490,501

    9   

 Sole Dispositive Power

 

 0

   10   

 Shared Dispositive Power

 

 276,490,501

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 276,490,501

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 8.9%

14  

 Type of Reporting Person

 

 IN


CUSIP No. 09063M205    13D    Page 6 of 8 pages

 

Explanatory Note

This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the “SEC”) on December 30, 2021, as amended to date (the “Schedule 13D”), relating to the ordinary shares, no par value per share (the “Ordinary Shares”), of Bionomics Limited, an Australian public company limited by shares (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

 

Item 5.

Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) – (b)

The following sets forth, as of the date of this Schedule 13D, the aggregate number of Ordinary Shares and percentage of Ordinary Shares beneficially owned by each of the Reporting Persons, as well as the number of Ordinary Shares as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 3,117,662,864 Ordinary Shares outstanding as of September 17, 2024 as reported by the Issuer on its Annual Report on Form 10-K filed on September 30, 2024.

 

Reporting Person

   Amount
beneficially
owned
     Percent
of class
    Sole power
to vote or
to direct
the vote
     Shared power
to vote or to
direct the vote
     Sole power
to dispose
or to direct

the
disposition
     Shared power
to dispose or
to direct the
disposition
 

Apeiron Investment Group, Ltd.

     276,490,501        8.9     0        276,490,501        0        276,490,501  

Apeiron Presight Capital Fund II, L.P.

     93,369,060        3.0     0        93,369,060        0        93,369,060  

Presight Capital Management I, L.L.C.

     93,369,060        3.0     0        93,369,060        0        93,369,060  

Fabian Hansen

     93,369,060        3.0     0        93,369,060        0        93,369,060  

Christian Angermayer

     276,490,501        8.9     0        276,490,501        0        276,490,501  

Presight II is the record holder of 518,717 ADSs representing 93,369,060 Ordinary Shares. Apeiron and Fabian Hansen are the managing members of Presight Management, which is the general partner of Presight II. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities held by Presight II.

In addition, Apeiron is the record holder of 146,279 ADSs (representing 26,330,220 Ordinary Shares) and 156,791,221 Ordinary Shares. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron.


CUSIP No. 09063M205    13D    Page 7 of 8 pages

 

(c)

During the past 60 days, Presight II sold 272,070 ADSs in open market transactions on the Nasdaq Global Market. Details by date, listing the number of shares sold and the price per share for transactions that were effected during the past sixty days are provided below.

 

Date

   Equity Shares
Disposed Of
     Price per Share  

October 2, 2024

     90,806      $ 0.33  

October 3, 2024

     180,707      $ 0.29  

October 4, 2024

     557      $ 0.28  

Except as described in above, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares.

 

(d)

None.

 

(e)

Not applicable.


CUSIP No. 09063M205    13D    Page 8 of 8 pages

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 7, 2024

 

Apeiron Investment Group, Ltd.
By:  

/s/ Mario Frendo

Name:   Mario Frendo
Title:   Director
Apeiron Presight Capital Fund II, L.P.

By: Presight Capital Management I, L.L.C., its general partner

By:  

/s/ Fabian Hansen

Name:   Fabian Hansen
Title:   Managing Member
Presight Capital Management I, L.L.C.
By:  

/s/ Fabian Hansen

Name:   Fabian Hansen
Title:   Managing Member
Fabian Hansen

/s/ Fabian Hansen

Christian Angermayer

/s/ Christian Angermayer


Bionomics (NASDAQ:BNOX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Bionomics
Bionomics (NASDAQ:BNOX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Bionomics